Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04752293 · ClinicalTrials.gov registry record

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

A clinical trial of Hypertension and Kidney Diseases, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
125
Enrollment target
1
Study location

NCT04752293 is a study of Hypertension and Kidney Diseases that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 125 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04752293, a study of Hypertension and Kidney Diseases, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
125 participants
Enrollment target
1
Study location

Study Summary

Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.

Study Locations (1)

North Carolina

  • Wake Forest Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2021-05-19
Est. Completion 2026-12

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT04752293

The ClinicalTrials.gov registry entry for NCT04752293 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Hypertension appearing as the primary indexed condition, and to 0 interventions.

NCT04752293 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT04752293 about?

NCT04752293 is a clinical study titled "Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)". Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, va...

What is the current status of trial NCT04752293?

This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2021-05-19. Estimated completion is 2026-12.

What conditions does trial NCT04752293 study?

This clinical trial studies the following conditions: Hypertension, Kidney Diseases, Kidney Injury, Left Ventricular Dysfunction, Left Ventricular Hypertrophy.

Who is sponsoring clinical trial NCT04752293?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04752293 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.